Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

Development of MRF for Characterization of Brain Tumors After Radiotherapy

Case Comprehensive Cancer Center · with The Cleveland Clinic · NCT06101069

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–60 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Not applicable
Target enrollment
90
US sites recruiting
2
Study start
October 14, 2024
Record last updated
October 20, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study is to discover the potential convenience and ease of using a Magnetic Resonance Imaging (MRI) technique, named Magnetic Resonance Fingerprinting (or MRF), to achieve high-quality images within a short scan time of 5 min for viewing the entire brain. This is an advanced quantitative assessment of brain tissues. This method is being applied with IVIM MRI to be able to tell the difference between a brain with radiation necrosis and a brain with tumor recurrence. Participants will consist of individuals who have received radiation therapy in the past and were diagnosed with radiation necrosis, individuals with recurrent tumors, individuals with previously untreated tumors, and healthy individuals who have no brain diseases and have not had radiation treatment to the brain. Participants will undergo an MRI scan at a one-time research study visit; no extra tests or procedures will be required for this research study.

The primary objectives of this study are

  • To demonstrate the clinical feasibility of combining MRF with state-of-the-art parallel imaging techniques to achieve high-resolution quantitative imaging within a reasonable scan time of 5 min for whole brain coverage.
  • To apply the developed quantitative approach in combination with IVIM MRI for differentiation of tumor recurrence and radiation necrosis.
  • To investigate the effect of radiation dose on the development of radiation necrosis and tumor recurrence.

Being studied: MRF in conjunction with IVIM MRI without contrast

Conditions: Brain Tumor; Brain Necrosis; Brain Metastases; Glioma

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria for Healthy Participants:

  • Ages 18 - 60
  • No history of cerebrovascular disease
  • No cognitive impairments
  • Able to provide informed consent

Inclusion Criteria for Participants with Brain Tumors:

  • Biopsy-proven cases of developed recurrent tumor or radiation necrosis, OR
  • a. PET identified with developed recurrent tumor or radiation necrosis. OR
  • b. Highly suspicious case with developed recurrent tumor or radiation necrosis confirmed by tumor board, attending physician or surgeon.
  • Age: 18 years and over
  • ECOG performance status 0-2.
  • Life expectancy > 6 months.
  • Participant with other sites of extracranial metastatic disease or any prior or current systemic therapies will be considered and evaluated by the investigators of the study on a subject basis.

Inclusion Criteria for Participants with Brain Metastases or Primary Gliomas:

  • Radiology identified with developed primary gliomas tumor or brain metastases, OR
  • a. PET identified with developed gliomas tumor or brain metastases, OR
  • b. Highly suspicious case with developed gliomas tumor or brain metastases confirmed by tumor board
  • Participants must not have received prior radiation or surgical treatment for brain metastases or primary glioma.
  • Age: 18 years and over
  • ECOG performance status 0-2
  • Life expectancy > 6 months.
  • Participant with other sites of extracranial metastatic disease or any prior or current systemic therapies will be considered and evaluated by the investigators of the study on a subject basis.

Inclusion Criteria for Participants with Meningiomas:

  • Radiology identified with resectable meningioma
  • Participants have no prior radiation or surgical treatment for brain lesions
  • Age: 18 years or older
  • ECOG performance status 0-2
  • Life expectancy > 6 months.
  • Participants with other sites of extracranial metastatic disease or any prior or current systemic therapies will be considered and evaluated by the investigators of the study on a subject basis.

Exclusion Criteria

  • Pregnant women OR lactating women
  • Participants with ferromagnetic or otherwise non-MRI compatible aneurysm clips.
  • Participants who cannot go into the MRI scanner due to metal implants and other medical conditions.
  • The presence of an implanted medical device that is not MRI-compatible, including, but not limited to: pacemaker, defibrillator.
  • Participants with contraindications for MRI due to embedded foreign metallic objects such as bullets, shrapnel, metalwork fragments, or other metallic material.
  • Known history of severe claustrophobia.
  • Participants under the age of 18
  • Participants unable to lay still in the scanner for 30 minutes at a time.

Recruiting US locations

  • University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center

    Cleveland, OH 44106

    Site contact: Chaitra A Badve, MD

  • Cleveland Clinic Taussig Cancer Center

    Cleveland, OH 44195

    Site contact: Lan Lu, PhD · 866-223-8100

Study contacts (from the official record)

  • Lan Lu, PhD · 1-866-223 8100 · TaussigResearch@ccf.org
All healthy volunteers studies in Ohio →
Development of MRF for Characterization of Brain Tumors After… (NCT06101069) | Bored Studies